Hims & Hers
The acquisition of the international telehealth company will allow Hims & Hers to expand its presence in Australia, Japan, Germany, Canada and the UK.
The pharma giant alleges that Hims & Hers is infringing its patents and misleading consumers by selling unsafe, unapproved compounded versions of its semaglutide drugs.
The partnership has been terminated less than two months after launch as Novo Nordisk alleges Hims & Hers is illegally selling copycat drugs and using deceptive marketing practices.
Through the acquisition, the company will expand its operations in the UK and launch operations in Germany, France and Ireland.
Americans with a prescription will have access to Novo Nordisk's obesity drug Wegovy through the Hims & Hers platform for $599 monthly.
The aim is to offer a broader range of personalized treatment options to patients.
Two U.S. senators and the Partnership for Safe Medicines sent letters to the FDA, raising concerns that the ad fails to disclose safety and side effect information required in pharmaceutical advertising.
Dr. Patrick Carroll, chief medical officer at Hims & Hers, describes the company's EMR and how its datasets power MedMatch, its new AI offering for mental health providers.
The partnership will give Hims & Hers clinicians the ability to link California patients to Carbon services.
The deal has brought the consumer telehealth and wellness company approximately $280 million in proceeds that it will use to grow and invest in new product categories.